Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy

INTRODUCTION: Drotrecogin alfa (activated) (DrotAA) is licensed in the United States and the European Union for the treatment of severe sepsis with multiple organ failure. Patients with severe sepsis on renal replacement therapy (RRT), who typically receive additional anticoagulation to prevent circ...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Camporota, Luigi, Corno, Eleonora, Menaldo, Eleonora, Smith, John, Lei, Katie, Beale, Richard, Wyncoll, Duncan
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2008
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2646328/
https://ncbi.nlm.nih.gov/pubmed/19094233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc7163
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items